ArticleJournal of nanobiotechnology2026
Novel Homo-SELEX for selecting universal aptamer for cross-species kidney injury biomarker KIM-1 in muti-scenario situ imaging.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Kidney injury molecule 1 (KIM-1) has emerged as a critical biomarker for renal injury, playing a pivotal role in disease diagnosis and therapeutic monitoring. Despite its clinical importance, the development of high-affinity molecular probes for KIM-1 remains challenging. Aptamers are valuable in biorecognition because of their easy synthesis, low toxicity and immunogenicity. The traditional Cell-SELEX suffers from poor cross-species compatibility, hindering its utility for KIM-1 detection. To overcome these challenges, we developed Homo-SELEX, an innovative cell-free SELEX strategy designed to screen aptamers against membrane proteins across multiple species. After 15 rounds of selection, universal aptamer S7 exhibited the highest affinity with different species of KIM-1. Aptamer S4 has specificity in identifying KIM-1 from homo sapiens and murine. The kidney tissue imaging demonstrated that S7 exhibited a better affinity than the S4. Furthermore, imaging of human clinical renal membranitis paraffin tissues, chronic kidney disease paraffin tissues of rats and acute nephrotoxic frozen tissues of mice, aptamer S7 exhibited a specific recognition of KIM-1. We also demonstrated the feasibility of S7 aptamer targeting KIM-1 in lung cancer A549 and liver injury tissues of rat and mouse, while demonstrating no binding to normal HK2 and tissue. Our works establish Homo-SELEX as a breakthrough strategy for homologous protein screening, with S7 serving as a robust, species-agnostic molecular probe for KIM-1 detection. This advancement holds significant promise for non-invasive diagnostics and targeted therapies for KIM-1-associated pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.